Document
type: Class

Academic Article
type: Class

Continuant
type: Class

Entity
type: Class

RDF description of Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN - http://irises.unisr.it/resource/item/218923
rights: termsOfUse
date: 2026-08-24T02:04:40
publisher: Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN
type: Document

417215880
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

Generically Dependent Continuant
type: Class

Article
type: Class

Inglese
type: Language

Information Content Entity
type: Class

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN
type: Thing
most specific type: Academic Article
type: Information Content Entity
related by: 417215880
type: Article
type: Generically Dependent Continuant
type: Entity
type: Document
type: Continuant
language: Inglese
type: Academic Article